시장보고서

상품코드

1983209

HPAPI 및 세포독성 약물 시장 : 약제 유래별, 제조 거점별, 약제 종류별, 약물 분자 종류별, 용도별, 지역별

HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin, By Manufacturing Location, By Drug Type, By Type of Pharmacological Molecule, By Application, By Geography

발행일: 2026년 02월 | 리서치사: 구분자

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

HPAPI 및 세포독성 약물 시장은 2026년에 377억 8,000만 달러로 추정되며, 2033년까지 648억 1,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 8%로 성장할 것으로 전망됩니다.

분석 범위		분석 상세
기준 연도	2025년	시장 규모(2026년)	377억 8,000만 달러
실적 데이터	2020-2024년	예측 기간	2026-2033년
예측 기간 CAGR(2026-2033년)	8.00%	예측 금액(2033년)	648억 1,000만 달러

HPAPI(고효능원료의약품)는 항암치료제를 포함한 의약품 파이프라인에서 점점 더 중요한 비중을 차지하고 있습니다. 고효능 API를 대량으로 생산하기 위해서는 HPAPI에 대한 풍부한 프로젝트 경험과 감사 및 공급 안정성에 대한 확실한 실적이 필요합니다.

세포독성 약물이란 세포분열을 억제하여 암세포나 종양을 파괴하기 위해 사용되는 약물을 말합니다. 이 약들은 항암제로 널리 사용되고 있으며, 수술이나 방사선 치료의 효과를 높이고, 전이를 억제하고, 암의 증상을 완화하는 데 사용됩니다.

시장 역학

시장 진입 기업들은 제품 포트폴리오를 확대하기 위해 인수와 같은 비유기적 성장 활동에 주력하고 있으며, 이는 예측 기간 동안 세계 HPAPI 및 세포독성 약물 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2019년 1월 생명과학 기업 플라마 그룹은 미국 말번에 위치한 4만 평방피트 규모의 cGMP 시설인 테바의 화학 합성 센터를 인수했습니다. 이 조사소 및 제조 기지에는 수소화 기능을 갖춘 cGMP 파일럿 플랜트, 습식 분쇄 시설, 5 개의 표준 cGMP 킬로랩 스위트, 1 개의 cGMP HPAPI 킬로랩 스위트를 갖추고 있습니다.

주요 기업들은 규제 당국으로부터 제조 시설 허가를 획득하는 데 주력하고 있으며, 이는 예측 기간 동안 세계 HPAPI 및 세포독성 약물 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2019년 12월 Cerbios-Pharma SA는 항체약물접합체(ADC)의 상업적 규모의 생산을 위한 cGMP 바이오 컨쥬게이션 스위트에 대해 스위스 메디(Swissmedic)로부터 승인을 받았다고 발표하였습니다.

또한, 2019년 12월에는 피라말 엔터프라이즈의 사업부인 피라말 파마 솔루션즈(Piramal Pharma Solutions Ltd.)가 미시간주 리버뷰에 위치한 제조시설을 확장하고 약 3,200만 달러를 투자하여 고활성 및 비고활성 원료의약품(API)의 개발 및 제조에 투자하였습니다.

본 보고서의 주요 특징

세계의 HPAPI 및 세포독성 약물 시장을 상세히 분석하고, 2021년을 기준 연도로 하여 예측 기간(2022-2030년)의 시장 규모와 CAGR을 조사하여 전해드립니다.
또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
세계 HPAPI 및 세포독성 약물 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등의 매개 변수를 기반으로 정리하여 전해드립니다.
이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
'세계 HPAPI 및 세포 독성 약물 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계 HPAPI 및 세포독성 약물 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 37.78 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.00%	2033 Value Projection:	USD 64.81 Bn

Highly potent active pharmaceutical ingredients (HPAPI) has an increasingly significant share of the pharmaceutical drug pipeline including anti-cancer treatments. Manufacturing highly potent APIs in large volumes requires extensive project experience with HPAPIs and a strong track record for audits and supply security.

Cytotoxic drugs are agents used to destroy cancer cells and tumors by inhibiting cell division. These drugs are widely used as anti-cancer agents and are used to boost the outcomes of surgery or radiotherapy, reduce metastasis, and diminish cancer symptoms.

Market Dynamics

Market players are engaged in inorganic activities, such as acquisitions, in order to expand its product portfolio, this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in January 2019, Flamma Group, a life science company, acquired Teva's Chemical Synthesis Center, the 40,000 sq. ft. cGMP facility in Malvern (U.S.). This laboratory and manufacturing site possesses a cGMP Pilot Plant with hydrogenation capabilities as well as wet-milling, 5 standard cGMP kilo lab suites, and 1 cGMP HPAPI kilo lab suite.

Key players are focusing on receiving authorizations for their manufacturing facilities, from the regulatory authorities, and this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in December 2019, Cerbios-Pharma SA announced the authorization by Swissmedic of its cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs).

Moreover, in December 2019, Piramal Pharma Solutions, a division of Piramal Enterprises ltd., expanded its manufacturing facility in Riverview, Michigan, with an investment of approximately US$ 32 million to develop and manufacture potent and non-potent active pharmaceutical ingredients (API).

Key features of the study

This report provides an in-depth analysis of the global HPAPIs and cytotoxic drugs manufacturing market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global HPAPIs and cytotoxic drugs manufacturing market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global HPAPIs and cytotoxic drugs manufacturing market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global HPAPIs and cytotoxic drugs manufacturing market

Market Segmentation

Drug Origin Insights (Revenue, USD Bn, 2026 - 2033)
- Chemical-based HPAPIs
- Biologic-based HPAPIs
Manufacturing Location Insights (Revenue, USD Bn, 2026 - 2033)
- In-house Manufacturing
- Outsourcing
Drug Type Insights (Revenue, USD Bn, 2026 - 2033)
- Novel HPAPIs
- Generic HPAPIs
Type of Pharmacological Molecule Insights (Revenue, USD Bn, 2026 - 2033)
- Small Molecules
- Biologics
Application Insights (Revenue, USD Bn, 2026 - 2033)
- Oncology
- Respiratory
- Ophthalmic Disorders
- Others
Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Lonza Group
- CordenPharma International
- Evonik Industries AG
- Flamma Group
- Merck KGaA
- CARBOGEN AMCIS
- Catalent, Inc.
- Piramal Enterprises Ltd.
- AbbVie Inc.
- Fareva Group
- Cerbios-Pharma SA
- Novasep
- Ajinomoto Bio-Pharma
- PCI Pharma Services
- Sterling Pharma Solutions
- Heraeus Holding
- Polpharma Biologics
- Helsinn Healthcare SA
- Seqens
- Cambrex Corporation

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Origin
- Market Snippet, By Manufacturing Location
- Market Snippet, By Drug Type
- Market Snippet, By Type of Pharmacological Molecule
- Market Snippet, By Application
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Regulatory Scenario
PEST Analysis
Recent Product Launch/Approval
Epidemiology
Mergers and Acquisitions

4. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin, 2026-2033 (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Chemical-based HPAPIs
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Biologic-based HPAPIs
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Manufacturing Location, 2026 - 2033 (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
In-house Manufacturing
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Outsourcing
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Type, 2026 - 2033 (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Novel HPAPIs
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Generic HPAPIs
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

7. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Small Molecules
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Biologics
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

8. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Application, 2026 - 2033 (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oncology
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Respiratory
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Ophthalmic Disorders
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

9. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Region, 2026 - 2033 (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
- Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
- Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
- Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
- Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
- Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Origin, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Manufacturing Location, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Drug Type, 2026 - 2033(USD Bn)
- Market Size and Forecast, By Type of Pharmacological Molecule, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Application, 2026 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2026 - 2033 (USD Bn)
  - South Africa
  - Central Africa
  - North Africa

10. Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Pfizer, Inc.
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Lonza Group
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Corden Pharma International
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Evonik Industries AG
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Flamma Group
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Merck KGaA
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- CARBOGEN AMCIS
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Catalent, Inc.
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Piramal Enterprises Ltd.
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- AbbVie Inc.
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Fareva Group
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Cerbios-Pharma SA
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Novasep
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Ajinomoto Bio-Pharma
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- PCI Pharma Services
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Sterling Pharma Solutions
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Heraeus Holding
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Polpharma Biologics
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Helsinn Healthcare SA
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Seqens
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Cambrex Corporation
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
  - Analyst Views

11. Section

References
Research Methodology
About us and Sales Contact

HPAPI 및 세포독성 약물 시장 : 약제 유래별, 제조 거점별, 약제 종류별, 약물 분자 종류별, 용도별, 지역별

HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin, By Manufacturing Location, By Drug Type, By Type of Pharmacological Molecule, By Application, By Geography

시장 역학

목차

제1장 분석 목적과 가정

제2장 시장 전망

제3장 시장 역학·규제·동향 분석

제4장 세계의 HPAPI 및 세포독성 약물 시장 : 약제 유래별(2026-2033년)

제5장 세계의 HPAPI 및 세포독성 약물 시장 : 제조 거점별(2026-2033년)

제6장 세계의 HPAPI 및 세포독성 약물 시장 : 약제 종류별(2026-2033년)

제7장 세계의 HPAPI 및 세포독성 약물 시장 : 약물 분자 종류별(2026-2033년)

제8장 세계의 HPAPI 및 세포독성 약물 시장 : 용도별(2026-2033년)

제9장 세계의 HPAPI 및 세포독성 약물 시장 : 지역별(2026-2033년)

제10장 경쟁 구도

제11장 섹션